Log in

NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

$13.89
+1.13 (+8.86 %)
(As of 04/10/2020 08:14 AM ET)
Add
Compare
Today's Range
$13.68
Now: $13.89
$14.85
50-Day Range
$8.75
MA: $12.55
$15.73
52-Week Range
$7.72
Now: $13.89
$16.96
Volume1.14 million shs
Average Volume897,409 shs
Market Capitalization$825.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More
Cytokinetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.87 million
Book Value($0.19) per share

Profitability

Net Income$-121,690,000.00
Net Margins-452.92%
Return on Equity-10,351.99%

Miscellaneous

Employees130
Market Cap$825.90 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 15.5% and is now trading at $13.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cytokinetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Cytokinetics.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) posted its earnings results on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.08. The biopharmaceutical company had revenue of $5.21 million for the quarter, compared to analyst estimates of $7.19 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 452.92%. View Cytokinetics' earnings history.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $28.03 million.

What price target have analysts set for CYTK?

6 brokers have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Cytokinetics' share price to reach $23.67 in the next twelve months. This suggests a possible upside of 70.4% from the stock's current price. View analysts' price targets for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

Media stories about CYTK stock have been trending very negative on Friday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutCytokinetics.

Are investors shorting Cytokinetics?

Cytokinetics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 7,830,200 shares, a drop of 6.1% from the February 27th total of 8,340,000 shares. Based on an average daily trading volume, of 749,000 shares, the days-to-cover ratio is currently 10.5 days. Approximately 14.4% of the shares of the stock are short sold. View Cytokinetics' Current Options Chain.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.09%) and Sanders Morris Harris LLC (0.02%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View institutional ownership trends for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, and State of Alaska Department of Revenue. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $13.89.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $825.90 million and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe. View additional information about Cytokinetics.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com/.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: Analyst Ratings Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel